Member of the Association of American Physicians
Apoptosis, Cancer research, Leukemia, Immunology and Cell biology are his primary areas of study. His Apoptosis research is multidisciplinary, relying on both Cell, Signal transduction and Mitochondrion. The study incorporates disciplines such as Cancer and Priming in addition to Mitochondrion.
His Cancer research study integrates concerns from other disciplines, such as Ex vivo, In vivo, Chemotherapy, MAPK/ERK pathway and Cancer cell. The concepts of his Leukemia study are interwoven with issues in Myeloid and Lymphoma. His Cell biology research is multidisciplinary, incorporating elements of Myeloid Cell Leukemia Sequence 1 Protein, Cell cycle, Activator and Molecular biology.
Anthony Letai mostly deals with Cancer research, Apoptosis, Cancer cell, Immunology and Cell biology. The Cancer research study combines topics in areas such as Venetoclax, Leukemia, Chronic lymphocytic leukemia, Lymphoma and In vivo. His research in Leukemia intersects with topics in Myeloid and Haematopoiesis.
His work deals with themes such as Cell, Priming, Cell culture and Mitochondrion, which intersect with Apoptosis. His study in Cancer cell is interdisciplinary in nature, drawing from both Ex vivo, Breast cancer, Pharmacology and Bioinformatics. His Cell biology research integrates issues from Bcl-2 family and Puma.
Anthony Letai mostly deals with Cancer research, Venetoclax, Apoptosis, Internal medicine and Oncology. His Cancer research research includes themes of Chronic lymphocytic leukemia, Priming, Lymphoma, Breast cancer and Mitochondrion. His biological study spans a wide range of topics, including Azacitidine, Myeloid leukemia, In vivo and Decitabine.
His work investigates the relationship between Apoptosis and topics such as Cell biology that intersect with problems in Enhancer. Anthony Letai combines subjects such as Chemotherapy and Drug with his study of Oncology. His Leukemia research incorporates themes from Myeloid and Transcription factor.
Anthony Letai focuses on Cancer research, Venetoclax, Apoptosis, Chronic lymphocytic leukemia and Myeloid. The various areas that Anthony Letai examines in his Cancer research study include Transcription factor, Phosphorylation, Kinase, Mitochondrion and MCL1. His Venetoclax research incorporates elements of Azacitidine, Vincristine, Decitabine and Lymphoma.
His work carried out in the field of Apoptosis brings together such families of science as Cell culture, Haematopoiesis, DNA damage, Cancer cell and Priming. His Cancer cell research is multidisciplinary, incorporating perspectives in Cytotoxic T cell, Cell and Cell biology. His research investigates the link between Myeloid and topics such as Myeloid leukemia that cross with problems in Leukemia, DNA methylation and DNA Methyltransferase Inhibitor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf;Steven W. Elmore;Alexander R. Shoemaker;Robert C. Armstrong.
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim;Craig H. Mermel;Craig H. Mermel;Dale Porter;Guo Wei.
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.
Anthony Letai;Michael C. Bassik;Loren D. Walensky;Mia D. Sorcinelli.
Cancer Cell (2002)
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.
Michael Certo;Victoria Del Gaizo Moore;Mari Nishino;Guo Wei.
Cancer Cell (2006)
Control of mitochondrial apoptosis by the Bcl-2 family.
Joslyn K. Brunelle;Anthony Letai.
Journal of Cell Science (2009)
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1
Joseph T. Opferman;Anthony Letai;Caroline Beard;Mia D. Sorcinelli.
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
Dharminder Chauhan;Laurence Catley;Guilan Li;Klaus Podar.
Cancer Cell (2005)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Courtney D. DiNardo;Keith Pratz;Vinod Pullarkat;Brian A. Jonas.
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
Victoria Del Gaizo Moore;Jennifer R. Brown;Michael Certo;Tara M. Love.
Journal of Clinical Investigation (2007)
Diagnosing and exploiting cancer's addiction to blocks in apoptosis
Anthony G. Letai.
Nature Reviews Cancer (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: